Phosphate toxicity and vascular mineralization

Contributions to Nephrology

Volumn 180, Issue , 2013, Pages 74-85

  Razzaque, Mohammed S ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,25-DIHYDROXYVITAMIN D; BETA GLUCURONIDASE; CALCITRIOL; DRUG DERIVATIVE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; HYDROXYAPATITE; KLOTHO PROTEIN; PHOSPHATE; VITAMIN D;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MODEL; GENETICS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCINOSIS; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYDROXYAPATITES; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MICE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES; VITAMIN D;

EID: 84925738149     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000346784     Document Type: Article

References (83)

1. Stary HC: Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr 2000; 72: 1297S-1306S.
2. Shroff RC, Shanahan CM: The vascular biology of calcification. Semin Dial 2007; 20: 103-109
3. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964
4. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
5. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216
6. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: Phosphate feeding induces arterial medial calcification in uremic mice: Role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307
7. Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP: Osteogenic regulation of vascular calcification. Ann NY Acad Sci 2006; 1068: 327-333
8. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B: FGF-23, vitamin D and calcification: The unholy triad. Nephrol Dial Transplant 2005; 20: 2032-2035
9. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404
10. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H: Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 1998; 433: 19-22
11. Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S: Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-794.
12. Gheduzzi D, Boraldi F, Annovi G, DeVincenzi CP, Schurgers LJ, Vermeer C, Quaglino D, Ronchetti IP: Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab Invest 2007; 87: 998-1008
13. Hur DJ, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA, Boyadjiev SA: A novel MGP mutation in a consanguineous family: Review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005; 135: 36-40
14. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD: Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 2003; 44(suppl 1):272-278
15. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78-81
16. Raggi P, Bellasi A: Clinical assessment of vascular calcification. Adv Chron Kid Dis 2007; 14: 37-43
17. Ossareh S: Vascular calcification in chronic kidney disease: Mechanisms and clinical implications. Iran J Kidney Dis 2011; 5: 285-299
18. Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464
19. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
20. Culleton BF, Hemmelgarn BR: Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial 2003; 16: 95-100
21. Levin A, Stevens L, McCullough PA: Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. Postgrad Med 2002; 111: 53-60
22. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
23. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
24. Pollak VE, Schneider AF, Freund G, Kark RM: Chronic renal disease with secondary hyperparathyroidism. AMA Arch Intern Med 1959; 103: 200-218
25. Parfitt AM: Soft-tissue calcification in uremia. Arch Intern Med 1969; 124: 544-556
26. Meema HE, Oreopoulos DG: Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology 1986; 158: 671-677
27. Merjanian R, Budoff M, Adler S, Berman N, Mehrotra R: Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64: 263-271
28. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
29. Chonchol M, Dale R, Schrier RW, Estacio R: Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med 2009; 122: 380-386
30. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T: Vitamin d and vascular calcification in chronic kidney disease. Bone 2009; 45(suppl 1):S26-S29
31. Contiguglia SR, Alfrey AC, Miller NL, Runnells DE, Le Geros RZ: Nature of soft tissue calcification in uremia. Kidney Int 1973; 4: 229-235
32. Reid JD, Andersen ME: Medial calcification (whitlockite) in the aorta. Atherosclerosis 1993; 101: 213-224
33. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA: Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-2596
34. Tukaj C, Kubasik-Juraniec J, Kraszpulski M: Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 2000; 6: 668-674
35. Rebsamen MC, Sun J, Norman AW, Liao JK: 1alpha,25-Dihydroxyvitamin D 3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91: 17-24
36. Tukaj C: Enhanced proliferation of aortal smooth muscle cells treated by 1,25(OH)2D3 in vitro coincides with impaired formation of elastic fibres. Int J Exp Pathol 2008; 89: 117-124
37. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382
38. Kalantar-Zadeh K, Kovesdy CP: Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1529-1539
39. Ohnishi M, Nakatani T, Lanske B, Razzaque MS: In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin D levels. Circ Cardiovasc Genet 2009; 2: 583-590
40. Gaasbeek A, Meinders AE: Hypophosphatemia: An update on its etiology and treatment. Am J Med 2005; 118: 1094-1101
41. ADHR-Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR consortium. Nat Genet 2000; 26: 345-348
42. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505
43. Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145: 5269-5279
44. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123
45. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M: Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428
46. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412
47. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical fgf receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774
48. Medici D, Razzaque MS, Deluca S, Rector TL, Hou B, Kang K, Goetz R, Mohammadi M, Kuro OM, Olsen BR, Lanske B: FGF-23-klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008; 182: 459-465
49. Nabeshima Y: The discovery of alpha-klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci 2008; 65: 3218-3230
50. Razzaque MS: FGF23-mediated regulation of systemic phosphate homeostasis: Is klotho an essential player? Am J Physiol Renal Physiol 2009; 296:F470-F476
51. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS: In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (FGF23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23: 433-441
52. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
53. Razzaque MS: Phosphate toxicity: New insights into an old problem. Clin Sci (Lond) 2011; 120: 91-97
54. Razzaque MS: Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011; 63: 240-247
55. Razzaque MS: The FGF23 klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619
56. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B: Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006; 20: 720-722
57. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B: Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008; 4:e1000154
58. Ohnishi M, Razzaque MS: Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010; 24: 3562-3571
59. Nabeshima Y: Toward a better understanding of klotho. Sci Aging Knowledge Environ 2006; 2006:pe11
60. Ohnishi M, Kato S, Razzaque MS: Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice. Biochem Biophys Res Commun 2011; 415: 434-438
61. Ohnishi M, Razzaque MS: Osteo-renal crosstalk and phosphate metabolism by fgf23-klotho system. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 1-13
62. Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque MS: Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J 2011; 25: 2031-2039
63. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW: High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916
64. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511
65. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
66. Wolisi GO, Moe SM: The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005; 18: 307-314
67. Osuka S, Razzaque MS: Can features of phosphate toxicity appear in normophosphatemia? J Bone Miner Metab 2012; 30: 10-18
68. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moyses RM, Jorgetti V: Phosphorus overload and PTH induce aortic expression of runx2 in experimental uraemia. Nephrol Dial Transplant 2009; 24: 1416-1421
69. Guntupalli J, Matthews B, Carlin B, Bourke E: Effect of acute hypercapnia on pth-stimulated phosphaturia in dietary Pi-deprived rat. Am J Physiol 1987; 253:F34-F40
70. Murer H, Evers C, Stoll R, Kinne R: The effect of parathyroid hormone (PTH) and dietary phosphate on the sodium-dependent phosphate transport system located in the rat renal brush border membrane. Curr Probl Clin Biochem 1977; 8: 455-462
71. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
72. Raggi P, Bommer J, Chertow GM: Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13: 134-141
73. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866
74. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Phosphate binder impact on bone remodeling and coronary calcification-results from the BRIC study. Nephron Clin Pract 2008; 110:c273-c283
75. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965
76. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
77. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
78. Shutto Y, Shimada M, Kitajima M, Yamabe H, Razzaque MS: Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks. PLoS One 2011; 6:e29105
79. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res 1999; 84: 166-178
80. Son BK, Kozaki K, Iijima K, Eto M, Nakano T, Akishita M, Ouchi Y: Gas6/Axl-PI3k/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007; 556: 1-8.
81. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y: Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006; 98: 1024-1031
82. Nakatani T, Ohnishi M, Razzaque MS: Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (HYP) mouse model. FASEB J 2009; 23: 3702-3711.
83. Razzaque MS: The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011; 79: 708-714